Olmesartan

Generic name
Olmesartan
Brand name
ATC Code
C09CA08
Compare …

Olmesartan

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information is present at this moment.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Hypertension
  • Oral
    • ≥ 6 years and < 35 kg
      • Initial dose: 10 mg/day in 1 dose
      • Maintenance dose: Depending on the response, increase if necessary to 20 mg/day in 1 dose
    • ≥ 6 years and ≥ 35 kg
      • Initial dose: 10 mg/day in 1 dose
      • Maintenance dose: Depending on the response, increase if necessary to 20 - 40 mg/day in 1 dose

Renal impaiment in children > 3 months

Adjustment in renal impairment as specified:

GFR 50-80 ml/min/1.73 m2
Dose adjustment not needed
GFR 30-50 ml/min/1.73 m2
50 percentage of single dose and dosing interval : 24 uur
GFR 10-30 ml/min/1.73 m2
50 percentage of single dose and dosing interval : 24 uur
GFR < 10 ml/min/1.73 m2
A general recommendation is not provided
Clinical consequences

With impaired renal function, the AUC of olmesartan increases. This increases the risk of adverse reactions.

Clinical implications:
The main problem with overdose is hypotension. Due to inhibition of the RAAS, some decline in renal function is possible. On the other hand, AT-II antagonists have a beneficial effect on renal function by reducing proteinuria and increasing urinary nitrate/nitrite excretion.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Dizziness, headaches and nosebleeds occur more often in children.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Angiotensin II receptor blockers (ARBs), plain
C09CA06
C09CA01
C09CA03

References

  1. Daiichi Sankyo Nederland B.V., SmPC Olmetec (RVG 28782) 10-05-2017, www.geneesmiddeleninformatiebank.nl
  2. NKFK Workinggroup Acute Kidney Impairment, Extrapolation of KNMP risk analysis "Impaired renal function" for adults to children, 20 Dec 2021

Changes

Therapeutic Drug Monitoring


Overdose